Mineralys Therapeutics' Lorundrostat NDA Accepted by FDA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy MLYS?
Mineralys Therapeutics announced that the FDA has accepted the new drug application, or NDA, for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs. The FDA has assigned a Prescription Drug User Fee Act, or PDUFA, target action date of December 22.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MLYS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MLYS
Wall Street analysts forecast MLYS stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 28.430
Low
46.00
Averages
52.60
High
56.00
Current: 28.430
Low
46.00
Averages
52.60
High
56.00
About MLYS
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. It has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). It is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and in subjects with hypertension and OSA.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Accepts Marketing Application for Mineralys' Lorundrostat
- FDA Application Accepted: Mineralys Therapeutics' marketing application for lorundrostat has been accepted by the FDA, marking a significant advancement in the treatment of hypertension, which is expected to enhance market recognition and investor confidence.
- Clinical Trial Results: In the Phase 2 Explore-OSA trial, although no clinically meaningful difference was observed in the primary endpoint, the significant reduction in blood pressure and favorable safety profile were deemed clinically meaningful, indicating the drug's potential in difficult-to-control hypertension patients.
- Market Outlook: The FDA has set a target action date of December 22, 2026, and if approved, this could open new revenue streams for the company and potentially secure a position in the competitive hypertension drug market.
- CEO Commentary: CEO Jon Congleton noted that despite the primary endpoint not being met, the drug's blood pressure-lowering effects and safety profile remain clinically significant, reflecting the company's ongoing commitment to developing new therapies.
See More
Mineralys Therapeutics' NDA for Lorundrostat Accepted by FDA
- FDA Acceptance: Mineralys Therapeutics announced that the FDA has accepted its New Drug Application for Lorundrostat, with a decision expected on December 22, 2026, marking a significant step in the company's potential market entry for hypertension treatment.
- Clinical Trial Success: The NDA submission is supported by three positive clinical trials demonstrating Lorundrostat's safety and ability to control blood pressure over 24 hours, indicating its potential as a new treatment option for uncontrolled hypertension.
- Explore-OSA Trial Findings: Although the Explore-OSA trial did not show a significant reduction in the apnea-hypopnea index (AHI), Lorundrostat demonstrated clinically meaningful blood pressure reductions and a favorable safety profile, enhancing its prospects for use in difficult-to-treat hypertension patients.
- Upcoming Financial Results: The company is set to report its financial results for Q4 and the full year 2025 on March 12, 2026, with investors keenly awaiting insights into the financial implications of its drug development progress.
See More
FDA Accepts Mineralys' NDA for Lorundrostat Targeting Hypertension
- FDA Approval Milestone: The FDA has accepted Mineralys Therapeutics' NDA for lorundrostat, with a target action date of December 22, 2026, marking a significant milestone in addressing the needs of patients with resistant hypertension.
- Clinical Trial Insights: The Explore-OSA trial demonstrated a clinically meaningful blood pressure reduction of 11.1 mmHg with lorundrostat, alongside a favorable safety profile, indicating its potential as a new treatment option for difficult-to-control hypertension.
- Significant Market Demand: Hypertension contributes to an economic burden of approximately $219 billion in the U.S., with around 30% of hypertensive patients experiencing difficulties due to dysregulated aldosterone, suggesting a substantial market opportunity for lorundrostat.
- Future Development Prospects: Mineralys plans to further validate lorundrostat's efficacy in upcoming clinical trials, potentially providing new treatment options for hypertension patients and driving growth in the biopharmaceutical sector.
See More
Chronic Kidney Disease Market Growth Drivers
- Market Size Growth: According to analysis, the chronic kidney disease (CKD) market size was approximately $4.8 billion in 2024 and is expected to grow further by 2034, reflecting increased demand for new therapies and an expanding patient base.
- Rising Patient Numbers: In 2024, there were about 82 million prevalent cases of CKD across the 7 major markets (7MM), with projections indicating continued growth from 2025 to 2034, primarily driven by an aging population and the rising prevalence of diabetes and hypertension.
- Launch of New Therapies: The introduction of emerging therapies such as AstraZeneca's Zibotentan/Dapagliflozin and Boehringer Ingelheim's Vicadrostat + Empagliflozin is expected to significantly boost market growth and improve treatment outcomes for patients.
- Advancements in Biomarkers: Progress in biomarkers like KIM-1 and NGAL enables more precise early detection of CKD, thereby enhancing the potential for timely interventions and improving overall patient prognosis.
See More
MLYS Stock 52-Week Highs and Lows Analysis
- Price Fluctuation Analysis: MLYS's 52-week low is $8.241 per share, while the high is $47.65, with the last trade at $28.26, indicating significant volatility in the stock price over the past year, reflecting varying market perceptions.
- Technical Indicator Focus: The current price of $28.26 is below the 200-day moving average, which may signal increased selling pressure in the short term, prompting investors to monitor subsequent market reactions to assess potential risks.
- Market Sentiment Assessment: Although the current price is significantly above the 52-week low, it remains below the high, suggesting a cautious market sentiment, necessitating investors to consider the overall market environment and the company's fundamentals in their decision-making.
- Investor Strategy Adjustment: Given the price fluctuations and changes in technical indicators, investors may need to reassess their holding strategies to manage potential market volatility and risk management needs.
See More
Mineralys Grants Stock Options to New Employees
- Stock Option Grants: On February 9, 2026, Mineralys Therapeutics awarded 33,504 stock options and 25,128 restricted stock units to two new non-executive employees, aimed at attracting talent and enhancing employee loyalty.
- Incentive Plan Details: The stock options will vest over four years, with 25% vesting in the first year and the remainder vesting at a rate of 1/48 each month, ensuring continued employee contributions during their tenure.
- Compliance Assurance: The grants comply with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to transparency and compliance in attracting new employees, which enhances investor confidence.
- Company Background: Mineralys focuses on developing medicines for hypertension and related comorbidities, with its lead candidate, lorundrostat, being an orally administered selective aldosterone synthase inhibitor, showcasing the company's innovative potential in the biopharmaceutical sector.
See More
FDA Accepts Marketing Application for Mineralys' Lorundrostat
- FDA Application Accepted: Mineralys Therapeutics' marketing application for lorundrostat has been accepted by the FDA, marking a significant advancement in the treatment of hypertension, which is expected to enhance market recognition and investor confidence.
- Clinical Trial Results: In the Phase 2 Explore-OSA trial, although no clinically meaningful difference was observed in the primary endpoint, the significant reduction in blood pressure and favorable safety profile were deemed clinically meaningful, indicating the drug's potential in difficult-to-control hypertension patients.
- Market Outlook: The FDA has set a target action date of December 22, 2026, and if approved, this could open new revenue streams for the company and potentially secure a position in the competitive hypertension drug market.
- CEO Commentary: CEO Jon Congleton noted that despite the primary endpoint not being met, the drug's blood pressure-lowering effects and safety profile remain clinically significant, reflecting the company's ongoing commitment to developing new therapies.
See More
Mineralys Therapeutics' NDA for Lorundrostat Accepted by FDA
- FDA Acceptance: Mineralys Therapeutics announced that the FDA has accepted its New Drug Application for Lorundrostat, with a decision expected on December 22, 2026, marking a significant step in the company's potential market entry for hypertension treatment.
- Clinical Trial Success: The NDA submission is supported by three positive clinical trials demonstrating Lorundrostat's safety and ability to control blood pressure over 24 hours, indicating its potential as a new treatment option for uncontrolled hypertension.
- Explore-OSA Trial Findings: Although the Explore-OSA trial did not show a significant reduction in the apnea-hypopnea index (AHI), Lorundrostat demonstrated clinically meaningful blood pressure reductions and a favorable safety profile, enhancing its prospects for use in difficult-to-treat hypertension patients.
- Upcoming Financial Results: The company is set to report its financial results for Q4 and the full year 2025 on March 12, 2026, with investors keenly awaiting insights into the financial implications of its drug development progress.
See More
FDA Accepts Mineralys' NDA for Lorundrostat Targeting Hypertension
- FDA Approval Milestone: The FDA has accepted Mineralys Therapeutics' NDA for lorundrostat, with a target action date of December 22, 2026, marking a significant milestone in addressing the needs of patients with resistant hypertension.
- Clinical Trial Insights: The Explore-OSA trial demonstrated a clinically meaningful blood pressure reduction of 11.1 mmHg with lorundrostat, alongside a favorable safety profile, indicating its potential as a new treatment option for difficult-to-control hypertension.
- Significant Market Demand: Hypertension contributes to an economic burden of approximately $219 billion in the U.S., with around 30% of hypertensive patients experiencing difficulties due to dysregulated aldosterone, suggesting a substantial market opportunity for lorundrostat.
- Future Development Prospects: Mineralys plans to further validate lorundrostat's efficacy in upcoming clinical trials, potentially providing new treatment options for hypertension patients and driving growth in the biopharmaceutical sector.
See More
Chronic Kidney Disease Market Growth Drivers
- Market Size Growth: According to analysis, the chronic kidney disease (CKD) market size was approximately $4.8 billion in 2024 and is expected to grow further by 2034, reflecting increased demand for new therapies and an expanding patient base.
- Rising Patient Numbers: In 2024, there were about 82 million prevalent cases of CKD across the 7 major markets (7MM), with projections indicating continued growth from 2025 to 2034, primarily driven by an aging population and the rising prevalence of diabetes and hypertension.
- Launch of New Therapies: The introduction of emerging therapies such as AstraZeneca's Zibotentan/Dapagliflozin and Boehringer Ingelheim's Vicadrostat + Empagliflozin is expected to significantly boost market growth and improve treatment outcomes for patients.
- Advancements in Biomarkers: Progress in biomarkers like KIM-1 and NGAL enables more precise early detection of CKD, thereby enhancing the potential for timely interventions and improving overall patient prognosis.
See More
MLYS Stock 52-Week Highs and Lows Analysis
- Price Fluctuation Analysis: MLYS's 52-week low is $8.241 per share, while the high is $47.65, with the last trade at $28.26, indicating significant volatility in the stock price over the past year, reflecting varying market perceptions.
- Technical Indicator Focus: The current price of $28.26 is below the 200-day moving average, which may signal increased selling pressure in the short term, prompting investors to monitor subsequent market reactions to assess potential risks.
- Market Sentiment Assessment: Although the current price is significantly above the 52-week low, it remains below the high, suggesting a cautious market sentiment, necessitating investors to consider the overall market environment and the company's fundamentals in their decision-making.
- Investor Strategy Adjustment: Given the price fluctuations and changes in technical indicators, investors may need to reassess their holding strategies to manage potential market volatility and risk management needs.
See More
Mineralys Grants Stock Options to New Employees
- Stock Option Grants: On February 9, 2026, Mineralys Therapeutics awarded 33,504 stock options and 25,128 restricted stock units to two new non-executive employees, aimed at attracting talent and enhancing employee loyalty.
- Incentive Plan Details: The stock options will vest over four years, with 25% vesting in the first year and the remainder vesting at a rate of 1/48 each month, ensuring continued employee contributions during their tenure.
- Compliance Assurance: The grants comply with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to transparency and compliance in attracting new employees, which enhances investor confidence.
- Company Background: Mineralys focuses on developing medicines for hypertension and related comorbidities, with its lead candidate, lorundrostat, being an orally administered selective aldosterone synthase inhibitor, showcasing the company's innovative potential in the biopharmaceutical sector.
See More
